We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PhaseBio Initiates Phase II Study for Coronavirus Patients
Read MoreHide Full Article
PhaseBio Pharmaceuticals, Inc. announced that it has dosed the first patient in a potentially pivotal phase II study, VANGARD, on its pipeline candidate, PB1046. The study will be assessing the efficacy and safety of once-weekly subcutaneous injections of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS).
The VANGARD study will enroll about 210 patients at about 20 sites nationwide. The primary endpoint in the study measures days alive and free of respiratory failure. Considering the pace of enrollment and any further impacts from the COVID-19 pandemic itself, the company expects to report initial data from the VANGARD study late in the fourth quarter of 2020.
Shares of the company have lost 10.1% year to date against the industry’s growth of 11.5%.
PB1046 is a novel, once-weekly, subcutaneously-injected vasoactive intestinal peptide (VIP) receptor agonist that targets VPAC receptors in the cardiovascular, pulmonary and immune systems. It has the potential to modulate several proinflammatory cytokines that are believed to be key drivers of the inflammatory response to COVID-19.
PhaseBio submitted an investigational new drug application (IND) to evaluate the potential of PB1046 to help COVID-19 patients at high risk of progressing to ARDS. The company received FDA clearance in May 2020 to initiate the VANGARD study.
The company is also developing PB1046 for the treatment of pulmonary arterial hypertension (PAH). It is in a phase II study for the same and results from the study are expected to be reported in 2021.
Emergent’s earnings per share estimates have increased from $3.14 to $4.23 for 2020 and from $3.35 to $4.31 for 2021 in the past 60 days.
BioMarin’s earnings per share estimates have increased from $1.51 to $1.56 for 2020 and from $2.46 to $2.79 for 2021 in the past 60 days.
BioDelivery’s earnings per share estimates have increased from 19 cents to 20 cents for 2020 and from 44 cents to 46 cents for 2021 in the past 60 days.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
PhaseBio Initiates Phase II Study for Coronavirus Patients
PhaseBio Pharmaceuticals, Inc. announced that it has dosed the first patient in a potentially pivotal phase II study, VANGARD, on its pipeline candidate, PB1046. The study will be assessing the efficacy and safety of once-weekly subcutaneous injections of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS).
The VANGARD study will enroll about 210 patients at about 20 sites nationwide. The primary endpoint in the study measures days alive and free of respiratory failure. Considering the pace of enrollment and any further impacts from the COVID-19 pandemic itself, the company expects to report initial data from the VANGARD study late in the fourth quarter of 2020.
Shares of the company have lost 10.1% year to date against the industry’s growth of 11.5%.
PB1046 is a novel, once-weekly, subcutaneously-injected vasoactive intestinal peptide (VIP) receptor agonist that targets VPAC receptors in the cardiovascular, pulmonary and immune systems. It has the potential to modulate several proinflammatory cytokines that are believed to be key drivers of the inflammatory response to COVID-19.
PhaseBio submitted an investigational new drug application (IND) to evaluate the potential of PB1046 to help COVID-19 patients at high risk of progressing to ARDS. The company received FDA clearance in May 2020 to initiate the VANGARD study.
The company is also developing PB1046 for the treatment of pulmonary arterial hypertension (PAH). It is in a phase II study for the same and results from the study are expected to be reported in 2021.
Zacks Rank & Other Stocks to Consider
PhaseBiocurrently carries a Zacks Rank #2 (Buy).
Some top-ranked stocks in the biotech sector are Emergent Biosolutions Inc. (EBS - Free Report) , BioMarin Pharmaceutical Inc. (BMRN - Free Report) and BioDelivery Sciences International Inc. , all carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings per share estimates have increased from $3.14 to $4.23 for 2020 and from $3.35 to $4.31 for 2021 in the past 60 days.
BioMarin’s earnings per share estimates have increased from $1.51 to $1.56 for 2020 and from $2.46 to $2.79 for 2021 in the past 60 days.
BioDelivery’s earnings per share estimates have increased from 19 cents to 20 cents for 2020 and from 44 cents to 46 cents for 2021 in the past 60 days.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>